Palbociclib
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Palbociclib: From Breast Cancer to Hyperthyroidism
One-Sentence Summary
Palbociclib is a CDK4/6 inhibitor whose evidence-pack literature consistently describes it as a treatment for HR+/HER2- metastatic breast cancer (the drug's own structured original-indication and MOA fields are data gaps). The TxGNN model's top prediction is Hyperthyroidism, but this ranking is supported by zero clinical trials and zero publications — it is a pure model output with no identifiable mechanistic rationale between CDK4/6 inhibition and thyroid hormone pathways.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in structured data (TFDA/NZ license text and original_indications are data gaps — DG001/DG002). Literature within this evidence pack repeatedly identifies palbociclib as a therapy for HR+/HER2- metastatic breast cancer. |
| Predicted New Indication | Hyperthyroidism |
| TxGNN Prediction Score | 99.44% |
| Evidence Level | L5 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap DG002). Based on the literature captured elsewhere in this evidence pack, palbociclib is a CDK4/6 inhibitor used for HR+/HER2- metastatic breast cancer, acting on the G1/S cell-cycle checkpoint.
For the top-ranked prediction, hyperthyroidism, the evidence pack's own rationale states there is no identifiable mechanistic link: CDK4/6 inhibition acts on cell-cycle regulation, with no known intersection with thyroid hormone synthesis, release, or receptor signaling. No clinical trials or publications support this candidate — it is a model-only association (TxGNN score 99.44%, evidence level L5).
This is a case where a high TxGNN score is not corroborated by mechanistic or literature evidence. By contrast, the pack's other ranked candidates carry more supporting information and are worth flagging for the record: rheumatoid arthritis (rank 2, L4) has four supporting publications, including a case report of RA improvement during palbociclib treatment and preclinical evidence of CDK6-dependent synovial hyperplasia; and thrombotic disease (rank 3, L4) is actually a safety signal, not a therapeutic lead — pharmacovigilance and cohort studies show CDK4/6 inhibitors are associated with an increased risk of thromboembolic events, the opposite of a treatment effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
New Zealand Market Information
Palbociclib is not currently marketed in New Zealand (0 authorizations on file; no license records available).
Cytotoxicity
Palbociclib is an antineoplastic agent (CDK4/6 inhibitor used in breast cancer, per the literature captured in this evidence pack).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (CDK4/6 inhibitor) |
| Myelosuppression Risk | High — the evidence pack's own literature notes palbociclib-induced myelosuppression (PMID 39940918) and describes bone marrow suppression as a common adverse event for this drug class (PMID 37994878) |
| Emetogenicity Classification | Not established in current evidence pack; refer to package insert |
| Monitoring Items | CBC with differential (neutropenia monitoring), liver and renal function |
| Handling Protection | Please refer to the package insert warnings and precautions; no TFDA/NZ label data available (DG001) |
Safety Considerations
Please refer to the package insert for safety information (key warnings, contraindications, and DDI data are all data gaps in this evidence pack).
Note from evidence review: although not part of the structured safety fields, the literature evidence gathered for the "thrombotic disease" candidate (rank 3) indicates CDK4/6 inhibitors, including palbociclib, are associated with an increased risk of thromboembolic events in real-world and pharmacovigilance studies (PMID 35300061, 36794339, 39123221, 39083396, 41496429). This should be treated as a safety consideration for any repurposing pathway, not a therapeutic signal.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (hyperthyroidism) has no supporting clinical trials, no supporting literature, and no identifiable mechanistic link — it is evidence level L5, a model-only association. There is insufficient basis to advance this indication.
To proceed, the following is needed:
- Original indication and MOA data for palbociclib (DrugBank API lookup — DG002)
- TFDA/NZ package insert warnings and contraindications (DG001)
- If pursuing repurposing further, prioritize the rheumatoid arthritis candidate (rank 2, L4, 4 supporting publications) over hyperthyroidism, which currently has no evidentiary basis
- Treat the thromboembolism signal surfaced under "thrombotic disease" (rank 3) as a safety monitoring item, not a repurposing candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.